Replimune Group (NASDAQ:REPL) Reaches New 52-Week High on Analyst Upgrade

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report)'s share price reached a new 52-week high on Friday after BMO Capital Markets raised their price target on the stock from $14.00 to $18.00. BMO Capital Markets currently has an outperform rating on the stock. Replimune Group traded as high as $15.46 and last traded at $15.34, with a volume of 794946 shares trading hands. The stock had previously closed at $11.05.

A number of other equities research analysts have also recently issued reports on REPL. JPMorgan Chase & Co. upped their target price on shares of Replimune Group from $14.00 to $17.00 and gave the company an "overweight" rating in a report on Tuesday, September 24th. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 price objective on shares of Replimune Group in a research report on Friday. Roth Capital raised Replimune Group to a "strong-buy" rating in a report on Tuesday, August 27th. Finally, Roth Mkm initiated coverage on Replimune Group in a report on Tuesday, August 27th. They set a "buy" rating and a $17.00 price target for the company. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Replimune Group has a consensus rating of "Buy" and a consensus price target of $17.00.

Insider Activity at Replimune Group

In related news, insider Konstantinos Xynos sold 7,246 shares of the firm's stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the transaction, the insider now directly owns 109,885 shares of the company's stock, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in REPL. Millennium Management LLC boosted its stake in shares of Replimune Group by 575.1% in the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company's stock valued at $28,062,000 after buying an additional 2,656,173 shares during the period. Braidwell LP lifted its position in shares of Replimune Group by 203.0% during the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company's stock valued at $33,656,000 after acquiring an additional 2,057,460 shares during the period. State Street Corp grew its holdings in shares of Replimune Group by 102.1% during the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company's stock worth $25,647,000 after purchasing an additional 1,182,181 shares in the last quarter. Baker BROS. Advisors LP increased its position in shares of Replimune Group by 10.0% in the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company's stock worth $121,057,000 after purchasing an additional 1,000,000 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its stake in Replimune Group by 12.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company's stock valued at $53,505,000 after purchasing an additional 699,679 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company's stock.

Replimune Group Stock Performance

The firm has a market cap of $1.02 billion, a price-to-earnings ratio of -4.90 and a beta of 1.19. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. The stock has a 50 day moving average of $11.59 and a 200 day moving average of $9.72.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping analysts' consensus estimates of ($0.75) by $0.07. As a group, analysts anticipate that Replimune Group, Inc. will post -3.02 EPS for the current fiscal year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.